Northwest Biotherapeutics
NWBO
NWBO was delisted on the 16th of December, 2016.
4 hedge funds and large institutions have $29K invested in Northwest Biotherapeutics in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 6 closing their positions.
50% less funds holding
Funds holding: 8 → 4 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less capital inflows, than outflows
Capital inflows: $7K | Capital outflows: $8.81M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Whalerock Point Partners
Providence,
Rhode Island
|
+$5K |
| 2 |
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodford Investment Management
London,
United Kingdom
|
-$8.64M |
| 2 |
CDH
Charles D. Hyman
|
-$87K |
| 3 |
Wedbush Securities
Los Angeles,
California
|
-$44K |
| 4 |
Brandes Investment Partners
La Jolla,
California
|
-$23K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$11K |
NWBO Hedge Fund Activity: Q1 2017 in Review
4 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q1 2017, worth a combined $29K — down 100% from $8.84M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NWBO and 2 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Whalerock Point Partners, opening a new position worth an estimated $5K. The largest seller was Woodford Investment Management, exiting entirely with an estimated $8.64M sold.
- 4 institutional investors held Northwest Biotherapeutics (NWBO) as of Q1 2017, down from 8 in Q4 2016.
- Funds reported $29K of Northwest Biotherapeutics stock for Q1 2017, down 100% quarter-over-quarter.
- 2 funds opened new Northwest Biotherapeutics positions in Q1 2017 and 6 closed out, a net change of -4 holders.
- The largest Northwest Biotherapeutics buyer in Q1 2017 was Whalerock Point Partners, an estimated $5K added.
- The largest Northwest Biotherapeutics seller in Q1 2017 was Woodford Investment Management, an estimated $8.64M sold.
Based on aggregated 13F filings for Q1 2017.